To include your compound in the COVID-19 Resource Center, submit it here.

NVA237 meets Phase III COPD endpoint

Novartis AG (NYSE:NVS; SIX:NOVN) said inhaled NVA237 met the primary endpoint in the Phase III GLOW2 trial to

Read the full 181 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE